| Ticker Details |
|
Aquestive Therapeutics, Inc.
|
| IPO Date: |
July 23, 2018 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers - Specialty and Generic |
| Market Cap: |
$531.98M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.17 | 4.00%
|
| Avg Daily Range (30 D): |
$0.12 | 2.81%
|
| Avg Daily Range (90 D): |
$0.10 | 2.39%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.98M |
| Avg Daily Volume (30 D): |
1.75M |
| Avg Daily Volume (90 D): |
1.61M |
| Trade Size |
| Avg Trade Size (Sh.): |
177 |
| Avg Trade Size (Sh.) (30 D): |
148 |
| Avg Trade Size (Sh.) (90 D): |
138 |
| Institutional Trades |
| Total Institutional Trades: |
312 |
| Avg Institutional Trade: |
$1.57M |
| Avg Institutional Trade (30 D): |
$1.72M |
| Avg Institutional Trade (90 D): |
$1.54M |
| Avg Institutional Trade Volume: |
.36M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.59M |
| Avg Closing Trade (30 D): |
$2.17M |
| Avg Closing Trade (90 D): |
$1.54M |
| Avg Closing Volume: |
341.24K |
|
|
| News |
May 2, 2026 @ 8:00 PM
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Enco...
Source: Rosen Law Firm
|
Apr 30, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Atara Biot...
Source: Bronstein, Gewirtz & Grossman Llc
|
Apr 30, 2026 @ 12:04 AM
Bragar Eagel & Squire, P.C. Reminds Aquestive Ther...
Source: Bragar Eagel & Squire, P.C.
|
Apr 28, 2026 @ 1:00 PM
Portnoy Law Firm Announces Class Action on Behalf ...
Source: Portnoy Law Firm
|
Apr 27, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Aquestive ...
Source: Bronstein, Gewirtz & Grossman Llc
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$-.07
|
$-.27
|
$-.78
|
|
Diluted EPS
|
$-.07
|
$-.27
|
$-.78
|
|
Revenue
|
$14.45M
|
$13.02M
|
$44.55M
|
|
Gross Profit
|
$10.98M
|
$7.18M
|
$25.99M
|
|
Net Income / Loss
|
$-8.06M
|
$-31.86M
|
$-83.78M
|
|
Operating Income / Loss
|
$-4.2M
|
$-28.84M
|
$-71.05M
|
|
Cost of Revenue
|
$3.47M
|
$5.84M
|
$18.56M
|
|
Net Cash Flow
|
$-10.44M
|
$-7.89M
|
$49.62M
|
|
PE Ratio
|
|
|
|
|
|
|